The relationships between clinicopathological features and survival in 171 patients with lung adenocarcinoma
| Variable | Total (%) | 5-year OS | P | ||
|---|---|---|---|---|---|
| Surviving (%) | Dead (%) | ||||
| Gender | 0.740 | ||||
| Male | 71 (41.5) | 41 (57.7) | 30 (42.3) | ||
| Female | 100 (58.5) | 61 (61) | 39 (39) | ||
| Age (years) | 0.270 | ||||
| <50 | 22 (12.9) | 16 (72.7) | 6 (27.3) | ||
| ≥50 | 149 (87.1) | 86 (57.7) | 63 (42.3) | ||
| History of smoking | 0.013* | ||||
| Absent | 102 (59.6) | 68 (66.7) | 34 (33.3) | ||
| Present | 69 (40.4) | 34 (49.3) | 35 (50.7) | ||
| Hypertension | 0.866 | ||||
| Absent | 123 (71.9) | 74 (60.2) | 49 (39.8) | ||
| Present | 48 (28.1) | 28 (58.3) | 20 (41.7) | ||
| Diabetes | 0.263 | ||||
| Absent | 161 (94.2) | 98 (60.9) | 63 (39.1) | ||
| Present | 10 (5.8) | 4 (40) | 6 (60) | ||
| Past history | 0.671 | ||||
| Absent | 160 (93.6) | 96 (60.0) | 64 (40.0) | ||
| Present | 11 (6.4) | 6 (54.5) | 5 (45.5) | ||
| Family tumor history | 0.805 | ||||
| Absent | 137 (80.1) | 81 (59.1) | 56 (40.9) | ||
| Present | 34 (19.9) | 21 (61.8) | 13 (38.2) | ||
| SCC (μg/L) | 0.794 | ||||
| ≤1.5 | 160 (93.6) | 95 (59.4) | 65 (40.6) | ||
| >1.5 | 11 (6.4) | 7 (63.6) | 4 (36.4) | ||
| TPSA (U/L) | 0.574 | ||||
| ≤80 | 142 (83.0) | 86 (60.6) | 56 (39.4) | ||
| >80 | 29 (17.0) | 16 (55.2) | 13 (44.8) | ||
| NSE (μg/L) | <0.001** | ||||
| ≤15.2 | 163 (95.3) | 102 (62.6) | 61 (37.4) | ||
| >15.2 | 8 (4.7) | 0 (0) | 8 (100) | ||
| CEA (μg/L) | <0.001** | ||||
| ≤5.0 | 102 (59.6) | 71 (69.6) | 31 (30.4) | ||
| >5.0 | 69 (40.4) | 31 (44.9) | 38 (55.1) | ||
| Cyfra21-1 (μg/L) | 0.020* | ||||
| ≤3.3 | 123 (71.9) | 80 (65.0) | 43 (35.0) | ||
| >3.3 | 48 (28.1) | 22 (45.8) | 26 (54.2) | ||
| Tumor size (cm) | <0.001** | ||||
| ≤3 | 122 (71.3) | 84 (68.9) | 38 (31.1) | ||
| >3 | 49 (28.7) | 18 (36.7) | 31 (63.3) | ||
| Lymph node metastasis | <0.001** | ||||
| Absent | 116 (67.8) | 87 (75.0) | 29 (25.0) | ||
| Present | 55 (32.2) | 15 (27.3) | 40 (72.7) | ||
| Distant metastasis | <0.001** | ||||
| Absent | 78 (45.6) | 72 (92.3) | 6 (7.7) | ||
| Present | 93 (54.4) | 30 (32.3) | 63 (67.7) | ||
| Histologic style | 0.017* | ||||
| Lepidic predominant | 28 (16.3) | 24 (85.7) | 4 (14.3) | ||
| Acinar predominant | 66 (38.6) | 38 (57.6) | 28 (42.4) | ||
| Papillary predominant | 16 (9.4) | 10 (62.5) | 6 (37.5) | ||
| Micropapillary predominant | 22 (12.9) | 8 (36.4) | 14 (63.6) | ||
| Solid predominant | 33 (19.3) | 20 (60.6) | 13 (39.4) | ||
| Mucinous predominant | 6 (3.5) | 2 (33.3) | 4 (66.7) | ||
| TNM stage | <0.001** | ||||
| I | 98 (57.3) | 83 (84.7) | 15 (15.3) | ||
| II | 16 (9.4) | 7 (43.8) | 9 (56.2) | ||
| III | 36 (21.0) | 11 (30.6) | 25 (69.4) | ||
| IV | 21 (12.3) | 1 (4.8) | 20 (95.2) | ||
*P < 0.05; **P < 0.01. SCC, squamous cell carcinoma antigen; TPSA, total prostate-specific antigen; NSE, neuron-specific enolase; CEA, carcino-embryonic antigen; Cyfra21-1, cytokeratin 19 fragments.